Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» donanemab
donanemab
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Setbacks reset views on highly touted Alzheimer's and ALS drugs
Axios
Mon, 03/11/24 - 05:06 pm
Alzheimer's disease
ALS
Amylyx
Relyvrio
Eli Lilly
donanemab
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
BioSpace
Fri, 03/8/24 - 11:55 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
Where’s Lilly’s Alzheimer’s approval?
Stat
Tue, 03/5/24 - 11:08 am
Eli Lilly
donanemab
Alzheimer's disease
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
Motley Fool
Fri, 11/10/23 - 12:19 pm
Eli Lilly
donanemab
tirzepatide
mirikizumab
lebrikizumab
pirtobrutinib
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Mon, 10/16/23 - 10:12 am
Alzheimer's disease
Biogen
Eisai
Eli Lilly
Leqembi
donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 12:34 pm
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi
Fierce Biotech
Mon, 07/17/23 - 06:51 pm
Eli Lilly
Alzheimer's disease
clinical trials
FDA
donanemab
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Thu, 05/11/23 - 11:14 am
Eli Lilly
donanemab
Alzheimer's disease
physicians
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
BioSpace
Thu, 05/4/23 - 10:27 am
Eli Lilly
Alzheimer's disease
donanemab
Lilly drug slows Alzheimer’s decline in large study
BioPharma Dive
Wed, 05/3/23 - 11:54 am
Eli Lilly
donanemab
clinical trials
Alzheimer's disease
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Wed, 04/26/23 - 09:59 am
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
Some Experts Say FDA Made the Right Call on Lilly's Donanemab
BioSpace
Tue, 01/24/23 - 10:31 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
RAPS.org
Sun, 01/22/23 - 01:00 pm
FDA
regulatory
clinical trials
clinicaltrials.gov
Eli Lilly
donanemab
Medtronic
BeiGene
Seagen
Innovative Trial Design may have Cost Lilly’s Donanemab Accelerated Approval
BioSpace
Fri, 01/20/23 - 10:29 am
Eli Lilly
donanemab
FDA
clinical trials
Alzheimer's disease
clinical trial design
Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug
Yahoo/Reuters
Thu, 01/19/23 - 09:00 pm
Eli Lilly
FDA
donanemab
Alzheimer's disease
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
Pages
1
2
3
next ›
last »